Asset Details
Do you wish to reserve the book?
Long-term experience of atrioventricular node ablation in patients with refractory atrial arrhythmias
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term experience of atrioventricular node ablation in patients with refractory atrial arrhythmias
Do you wish to request the book?
Long-term experience of atrioventricular node ablation in patients with refractory atrial arrhythmias
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term experience of atrioventricular node ablation in patients with refractory atrial arrhythmias
2020
Overview
Atrial fibrillation and other atrial tachyarrhythmias are increasing with age and concomitant morbidity. First options in symptomatic patients are drug treatment and catheter ablation. Nevertheless, a considerable number of patients suffer from refractory atrial tachyarrhythmias despite treatment. Atrioventricular node ablation (AVNA) may be helpful in many of these patients. Therefore, we investigated AVNA patients with a long-term follow-up. We enrolled 82 patients with a follow-up longer than 1 year receiving AVNA for drug- and ablation-resistant atrial tachyarrhythmias (AA) in a retrospective manner. Mean follow-up duration was 48 ± 24 months. 50% of the patients initially received AVNA to optimize biventricular pacing in cardiac resynchronization therapy, the other 50% because of refractory symptomatic tachyarrhythmias. Persistent AV block was achieved in every patient. Symptom relief and patient satisfaction were high during follow-up. Due to system upgrades there were 63% of patients with a biventricular system during follow-up. In these patients, left-ventricular ejection fraction (LV-EF) increased by 7% (42–49%) after ablation. AVNA is effective in increasing biventricular pacing as well as for symptom relief in patients with refractory atrial tachyarrhythmias. AVNA should be considered as a valuable option in patients with refractory atrial tachyarrhythmias lacking other treatment options.
Publisher
Springer Japan,Springer Nature B.V
Subject
/ Aged
/ Atrial Fibrillation - diagnosis
/ Atrial Fibrillation - physiopathology
/ Atrial Fibrillation - surgery
/ Atrioventricular Node - physiopathology
/ Atrioventricular Node - surgery
/ Biomedical Engineering and Bioengineering
/ Catheter Ablation - adverse effects
/ Female
/ Heart
/ Humans
/ Male
/ Medicine
/ Sepsis
/ Tachycardia, Supraventricular - diagnosis
/ Tachycardia, Supraventricular - physiopathology
